INO-1001 / Rocket Pharma, Roche - LARVOL DELTA

Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease. (PubMed, Front Neuroanat) - "Moreover, INO-1001 promoted CBP localization into the nuclei of the R6/2 mouse. The sum of our data corroborates the previous observations indicating PARP inhibition as a possible therapeutic tool to fight HD."

Journal • Biosimilar • Cardiovascular • CNS Disorders • Ophthalmology • Reperfusion Injury

PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease. (PubMed) - "INO-1001 was effective in significantly increasing activated CREB and BDNF in the striatal spiny neurons, which might account for the beneficial effects observed in this model. Our findings show that PARP-1 inhibition could be considered as a valid therapeutic approach for HD."

Journal • Biosimilar

PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis. (PubMed, Exp Cell Res) - "PARP1 inhibitor INO1001 attenuated cardiomyopathic features in diabetic mice through the activation of SIRT1 and its downstream antioxidant defence mechanisms. The results of this study suggest a pivotal role of PARP-1 inhibition in treating diabetic and AT-induced cardiomyopathy."

Journal • PARP Biomarker